Moderate To Severe Systemic Lupus Erythematosus Sle clinical trials

Explore recruiting moderate to severe systemic lupus erythematosus sle clinical trials.

Recruiting moderate to severe systemic lupus erythematosus sle studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate To Severe Systemic Lupus Erythematosus Sle trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)

Bulgaria, Romania, France, Germany, Spain, Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus

Hungary, Spain, Bulgaria, Germany, Poland

Phase II and Phase III (Integrated) EU CTIS Study details

Randomised, placebo-controlled, double-blind, parallel-group Phase II study to evaluate the efficacy and safety of oral BI 3000202 in patients with moderate to severe systemic lupus erythematosus (SLE)

Bulgaria, Romania, Germany, Spain, Hungary, Poland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy (OPUS OLE)

France, Portugal, Poland, Germany, Spain, Czechia +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

OPUS-2 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy

Spain, Germany, Portugal, Poland, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

OPUS-1 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy

France, Greece, Poland, Bulgaria, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Moderate To Severe Systemic Lupus Erythematosus Sle trials by city

Moderate To Severe Systemic Lupus Erythematosus Sle in Toronto Moderate To Severe Systemic Lupus Erythematosus Sle in Vancouver Moderate To Severe Systemic Lupus Erythematosus Sle in Montreal Moderate To Severe Systemic Lupus Erythematosus Sle in Calgary Moderate To Severe Systemic Lupus Erythematosus Sle in Edmonton Moderate To Severe Systemic Lupus Erythematosus Sle in Ottawa Moderate To Severe Systemic Lupus Erythematosus Sle in Winnipeg Moderate To Severe Systemic Lupus Erythematosus Sle in Quebec City Moderate To Severe Systemic Lupus Erythematosus Sle in Hamilton Moderate To Severe Systemic Lupus Erythematosus Sle in Kitchener Moderate To Severe Systemic Lupus Erythematosus Sle in London Moderate To Severe Systemic Lupus Erythematosus Sle in Halifax Moderate To Severe Systemic Lupus Erythematosus Sle in New York Moderate To Severe Systemic Lupus Erythematosus Sle in Los Angeles Moderate To Severe Systemic Lupus Erythematosus Sle in Chicago Moderate To Severe Systemic Lupus Erythematosus Sle in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease